Personalis wins expanded Medicare coverage for NeXT Personal immunotherapy monitoring test

Personalis

Personalis

PSNL

0.00
  • CMS MolDX expanded Medicare coverage for Personalis NeXT Personal MRD test to include immunotherapy monitoring in late-stage solid tumors.
  • Decision broadens reimbursement access for ultrasensitive blood-based monitoring to gauge treatment response ahead of imaging.
  • Coverage backed by published clinical data generated with Vall d'Hebron Institute of Oncology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605130600BIZWIRE_USPR_____20260513_BW278817) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.